30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: DePuy Synthes/Johnson & Johnson

$2,385MM, +61% (U.S. $1,261MM, +61%, ex-U.S. $1,124MM, +61%)

  • Hips +2% (U.S. +5%, ex-U.S. -0.2%)
  • Knees -0.5% (U.S. +0.5%, ex-U.S. -2%)
  • Trauma +2% (U.S. +2%, ex-U.S. +2%)
  • Spine -7% (U.S. -10%, ex-U.S. -3%) (Including Synthes, -5%)
  • Sports Med +5% (U.S. +11%, ex-U.S. -1.3%)

 

  • Overall growth includes Synthes; excludes trauma divestiture. Synthes ~14% of worldwide sales
  • Excluding Synthes & trauma divestiture, overall growth +2%
  • Slight improvement in healthcare utilization from end of 2012 did not carry into 1Q13; no meaningful acceleration in trend expected for 2013
  • Strong primary hip stem sales, partially offset by price pressure
  • Hip sales strong in emerging market sales
  • Strong U.S. fixed bearing and revision knee sales, offset by lower sales of rotating platforms
  • Lower ex-U.S. sales of LSC and mobile bearing technology
  • Spine distribution restructuring still disrupting growth
  • U.S. pricing: hips -4%; knees -2%; spine -3% price/positive 4% mix, so 1% positive)